Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Non-Current Assets: 2022-2025

Historic Non-Current Assets for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to $7.1 million.

  • Addex Therapeutics' Non-Current Assets fell 29.07% to $7.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $7.1 million, marking a year-over-year decrease of 29.07%. This contributed to the annual value of $8.1 million for FY2024, which is 1688.95% up from last year.
  • Latest data reveals that Addex Therapeutics reported Non-Current Assets of $7.1 million as of Q2 2025, which was up 1.02% from $7.0 million recorded in Q1 2025.
  • In the past 5 years, Addex Therapeutics' Non-Current Assets registered a high of $10.0 million during Q2 2024, and its lowest value of $45,125 during Q1 2024.
  • For the 3-year period, Addex Therapeutics' Non-Current Assets averaged around $4.3 million, with its median value being $3.7 million (2023).
  • As far as peak fluctuations go, Addex Therapeutics' Non-Current Assets tumbled by 89.01% in 2024, and later spiked by 15,397.26% in 2025.
  • Quarterly analysis of 4 years shows Addex Therapeutics' Non-Current Assets stood at $470,316 in 2022, then decreased by 2.37% to $459,149 in 2023, then surged by 1,674.36% to $8.1 million in 2024, then decreased by 29.07% to $7.1 million in 2025.
  • Its Non-Current Assets stands at $7.1 million for Q2 2025, versus $7.0 million for Q1 2025 and $8.1 million for Q4 2024.